COVID-19 and pregnancy: A European study on pre- and post-infection medication use.

Autor: Hurley E; PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway., Geisler BP; PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Lupattelli A; PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway., Poblador-Plou B; EpiChron Research Group, Aragon Health Sciences Institute, Miguel Servet University Hospital, Saragossa, Spain.; Network for Research on Chronicity, Primary Care, and Health Promotion, Research Network on Health Services in Chronic Diseases, Institute of Health Carlos III, Madrid, Spain., Lassalle R; Bordeaux PharmacoEpi, Plateforme de recherche en Pharmaco-épidémiologie, Bordeaux, France., Jové J; Bordeaux PharmacoEpi, Plateforme de recherche en Pharmaco-épidémiologie, Bordeaux, France., Bernard MA; Bordeaux PharmacoEpi, Plateforme de recherche en Pharmaco-épidémiologie, Bordeaux, France., Sakr D; Bordeaux PharmacoEpi, Plateforme de recherche en Pharmaco-épidémiologie, Bordeaux, France., Sanfélix-Gimeno G; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region, Valencia, Spain., Sánchez-Saez F; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region, Valencia, Spain., Rodríguez-Bernal CL; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region, Valencia, Spain., Sabaté M; Department of Clinical Pharmacology, Vall d`Hebron Hospital Universitari, Vall Hebron Institut de Recerca, Barcelona, Spain., Ballarín E; Department of Clinical Pharmacology, Vall d`Hebron Hospital Universitari, Vall Hebron Institut de Recerca, Barcelona, Spain., Aguilera C; Department of Clinical Pharmacology, Vall d`Hebron Hospital Universitari, Vall Hebron Institut de Recerca, Barcelona, Spain., Jordan S; Faculty of Medicine, Health and Life Science, Swansea University, Swansea, Wales, UK., Thayer D; Faculty of Medicine, Health and Life Science, Swansea University, Swansea, Wales, UK., Farr I; Faculty of Medicine, Health and Life Science, Swansea University, Swansea, Wales, UK., Ahmed S; Faculty of Medicine, Health and Life Science, Swansea University, Swansea, Wales, UK., Bartolini C; Agenzia Regionale di Sanità della Toscana, Florence, Italy., Limoncella G; Agenzia Regionale di Sanità della Toscana, Florence, Italy., Paoletti O; Agenzia Regionale di Sanità della Toscana, Florence, Italy., Gini R; Agenzia Regionale di Sanità della Toscana, Florence, Italy., Maglanoc LA; IT Department, Data Management, University of Oslo, Oslo, Norway., Dudukina E; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark., Ehrenstein V; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark., Alsina E; Department of Data Science and Biostatistics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands., Vaz TA; Department of Data Science and Biostatistics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands., Riera-Arnau J; Department of Clinical Pharmacology, Vall d`Hebron Hospital Universitari, Vall Hebron Institut de Recerca, Barcelona, Spain.; Department of Data Science and Biostatistics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands., Sturkenboom MCJM; Department of Data Science and Biostatistics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands., Nordeng HME; PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway. h.m.e.nordeng@farmasi.uio.no.; Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway. h.m.e.nordeng@farmasi.uio.no.
Jazyk: angličtina
Zdroj: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2024 May; Vol. 80 (5), pp. 707-716. Date of Electronic Publication: 2024 Feb 12.
DOI: 10.1007/s00228-024-03639-z
Abstrakt: Purpose: The COVID-19 pandemic has impacted medication needs and prescribing practices, including those affecting pregnant women. Our goal was to investigate patterns of medication use among pregnant women with COVID-19, focusing on variations by trimester of infection and location.
Methods: We conducted an observational study using six electronic healthcare databases from six European regions (Aragon/Spain; France; Norway; Tuscany, Italy; Valencia/Spain; and Wales/UK). The prevalence of primary care prescribing or dispensing was compared in the 30-day periods before and after a positive COVID-19 test or diagnosis.
Results: The study included 294,126 pregnant women, of whom 8943 (3.0%) tested positive for, or were diagnosed with, COVID-19 during their pregnancy. A significantly higher use of antithrombotic medications was observed particularly after COVID-19 infection in the second and third trimesters. The highest increase was observed in the Valencia region where use of antithrombotic medications in the third trimester increased from 3.8% before COVID-19 to 61.9% after the infection. Increases in other countries were lower; for example, in Norway, the prevalence of antithrombotic medication use changed from around 1-2% before to around 6% after COVID-19 in the third trimester. Smaller and less consistent increases were observed in the use of other drug classes, such as antimicrobials and systemic corticosteroids.
Conclusion: Our findings highlight the substantial impact of COVID-19 on primary care medication use among pregnant women, with a marked increase in the use of antithrombotic medications post-COVID-19. These results underscore the need for further research to understand the broader implications of these patterns on maternal and neonatal/fetal health outcomes.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: